SOUTH PLAINFIELD, N.J., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Molecular Diagnostics company, Admera Health, (www.admerahealth.com) announced today that it received New York State Clinical Laboratory Evaluation Program (CLEP) approval for its 25 gene PGxOne™ Plus pharmacogenomics (PGx) test. 

“This approval is a major milestone for Admera and exemplifies our aptitude to deliver molecular diagnostics that meet the highest quality standards,” said Guanghui Hu, PhD, President and CEO of Admera Health. “We are pleased to be able to offer New York residents clinical PGx testing. Results can guide effective treatment decisions, potentially reducing adverse drug events and trial-and-error drug selection and dosing. Furthermore, our report provides valuable information about harmful drug-drug, drug-food, drug-alcohol and drug-laboratory test interactions.”

PGxOne™ Plus leverages Next Generation Sequencing (NGS) technology to interrogate 25 genes with associated PGx information. Test results help predict how patients will respond to drug therapy for several therapeutic areas including, but not limited to, cardiology, psychiatry, pain management, and oncology. Examples of recommendations provided in the report are: consider alternatives when specific drugs should be avoided, adjust dose, use with caution, or normal response expected.

Recently, Admera updated the PGxOne™ Plus panel to include an additional 25 genes, bringing the number of drugs whose metabolism is affected to over 220.

Dr. Hu went on to elaborate, “This is our first step in providing NGS-based molecular diagnostics solutions in New York. We are forging ahead with plans to have our recently updated 50 gene PGxOne™ Plus panel available there, making it available in all 50 states.”

In addition to PGx testing, Admera Health offers clinical testing for the risk assessment and diagnosis of inherited cardiovascular diseases and cancer tumor profiling to guide selection of targeted therapies.

About Admera Health

Admera Health is a CLIA-certified and CAP-accredited advanced molecular diagnostics company focused on personalized medicine, non-invasive cancer testing, digital health, and providing research use only services. Research and development efforts are dedicated to developing cutting-edge diagnostics that span the continuum of care. Utilizing next generation technology platforms and advanced bioinformatics, Admera Health seeks to redefine disease screening, diagnosis, treatment, monitoring, and management through its innovative, personalized solutions. It is our mission to deliver transformative, valuable solutions for patients, physicians, and clinical researchers. We are committed to improving the health and well-being of our global community through the direct delivery of personalized, medically actionable results.

Admera Health Contact:

Brady Millican, VP Business Development
908-222-0533
brady.millican@admerahealth.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.